Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

161. Irritable bowel syndrome: a little understood organic bowel disease? (PubMed)

Irritable bowel syndrome: a little understood organic bowel disease? Irritable bowel syndrome affects 10% of adults with an unexplained female predominance. Although only a few people see their family doctor, the disease causes reduced quality of life and represents a multi-billion pound health-care problem. The disorder clusters in families, which is possibly because of intra-familial learning and a genetic predisposition. Visceral hypersensitivity is a key feature in most patients. Results (...) of imaging studies of regional cerebral blood flow during rectal distension suggest underlying disturbances of central processing of afferent signals, though this is not unique to the disorder, since it is seen in other chronic pain syndromes. Environmental factors that are strongly implicated in at least some patients include gastrointestinal infection and inflammation and chronic stress. Diagnosis is based on positive symptoms and absence of any alarm indicators. Treatment remains unsatisfactory

2002 Lancet

162. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review

The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 DARE.

163. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. (PubMed)

Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Irritable bowel syndrome has a high prevalence. Consensus diagnostic criteria (ROME II) based on symptoms have been established to aid diagnosis. Although coeliac disease can be misdiagnosed as irritable bowel syndrome, no prospective study has been published in which patients with this disorder are investigated for coeliac disease. We (...) aimed to assess the association of coeliac disease with irritable bowel syndrome in patients fulfilling ROME II criteria.We undertook a case-control study at a university hospital. 300 consecutive new patients who fulfilled Rome II criteria for irritable bowel syndrome, and 300 healthy controls (age and sex matched) were investigated for coeliac disease by analysis of serum IgA antigliadin, IgG antigliadin, and endomysial antibodies (EMA). Patients and controls with positive antibody results were

2001 Lancet

164. Tegaserod (Zelmac) (irritable bowel syndrome)

Tegaserod (Zelmac) (irritable bowel syndrome) Tegaserod (Zelmac) (irritable bowel syndrome) Tegaserod (Zelmac) (irritable bowel syndrome) Stachnik J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stachnik J. Tegaserod (Zelmac) (irritable bowel syndrome) University HealthSystem Consortium (UHC). Drug Monograph. 2001 Authors' objectives The UHC Drug Monographs

2001 Health Technology Assessment (HTA) Database.

165. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome Poynard T, Regimbeau C, Benhamou Y Authors' objectives To assess the efficacy and tolerance of smooth muscle relaxants in the treatment of irritable bowel syndrome (IBS). Searching A search of MEDLINE and a manual search were combined (...) . The keywords used were 'colonic disease', 'functional', irritable bowel syndrome' and 'randomised trial'. Additional studies were obtained by examining general reviews, references from published RCTs, and Current Contents, and by contacting pharmaceutical companies. In addition, recent meta-analyses in the Journal of Hepatogastroenterology were also used. Only published articles were considered for the review. Study selection Study designs of evaluations included in the review Only double-blind, placebo

2001 DARE.

166. Treatment of irritable bowel syndrome: a review of randomised controlled trials

Treatment of irritable bowel syndrome: a review of randomised controlled trials Treatment of irritable bowel syndrome: a review of randomised controlled trials Treatment of irritable bowel syndrome: a review of randomised controlled trials Akehurst R, Kaltenthaler E Authors' objectives To review and assess published randomised controlled trials (RCTs) examining the clinical effectiveness of interventions for irritable bowel syndrome (IBS) treatments. Searching The Cochrane Library, DARE (...) of this review. Research: The authors state that 'it is essential that RCTs are conducted of consistently identified patients with clearly defined outcome measures. These outcome measures should not only deal with symptom relief but also improvement in quality of life and associated measures such as time off work'. Bibliographic details Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48(2): 272-282 PubMedID Original Paper URL Other

2001 DARE.

167. Cost-effectiveness of endoscopy in irritable bowel syndrome

Cost-effectiveness of endoscopy in irritable bowel syndrome Cost-effectiveness of endoscopy in irritable bowel syndrome Cost-effectiveness of endoscopy in irritable bowel syndrome Suleiman S, Sonnenberg A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The use of flexible sigmoidoscopy and colonoscopy in the diagnosis of irritable bowel syndrome. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population The study investigated patients possibly suffering from IBS. Setting Hospital. The study was set in the USA. Dates to which data relate Effectiveness and resource use data were collected from studies published between 1977 and 1999. Cost data were taken from sources published

2001 NHS Economic Evaluation Database.

168. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. (PubMed)

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with symptoms of abdominal pain, discomfort, and altered bowel function. Antagonists of the type 3 serotonin receptor (5-HT3) have shown promising results in the relief of IBS-associated symptoms. We aimed to confirm these findings by doing a randomised, placebo-controlled trial.We studied 647 female IBS patients (...) with diarrhoea-predominant or alternating bowel patterns (diarrhoea and constipation). 324 patients were assigned 1 mg alosetron and 323 placebo orally twice daily for 12 weeks, followed by a 4-week post-treatment period. Adequate relief of abdominal pain and discomfort was the primary endpoint; secondary endpoints included improvements in urgency, stool frequency, and stool consistency. Analysis was by intention to treat.79 (24%) of patients in the alosetron group and 53 (16%) in the placebo group dropped

2000 Lancet

169. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials Jailwala J, Imperiale T F, Kroenke K Authors' objectives To evaluate the efficacy of pharmacological agents for the irritable bowel syndrome. Searching Articles published (...) ; and combinations of two to three of these agents. Co-interventions included dietary changes such as high fibre diet, and concurrent use of other medications. Participants included in the review Adult patients with irritable bowel syndrome were eligible. Mean age ranged from 24 to 51 years (median 38 years). An average of 68% of participants were women. The following means were used to diagnose irritable bowel syndrome: standard criteria (including the Rome and Manning criteria); operational criteria based

2000 DARE.

170. Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome

Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome McGahan L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Lotronex (TM): therapy for diarrhea predominant (...) irritable bowel syndrome. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2000: 4 Authors' objectives To summarise the available evidence on Lotronex (TM) for diarrhea predominant irritable bowel syndrome (IBS). Authors' conclusions Lotronex (TM) has been approved for marketing in the United States for the treatment of IBS in women whose predominant symptom is diarrhea. Lotronex (TM) has not yet

2000 Health Technology Assessment (HTA) Database.

171. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. (PubMed)

Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. Irritable bowel syndrome (IBS) is a common functional bowel disorder for which there is no reliable medical treatment.To determine whether Chinese herbal medicine (CHM) is of any benefit in the treatment of IBS.Randomized, double-blind, placebo-controlled trial conducted during 1996 through 1997.Patients were recruited through 2 teaching hospitals and 5 private practices of gastroenterologists (...) , and herbalists were all blinded to treatment group.Change in total bowel symptom scale scores and global improvement assessed by patients and gastroenterologists and change in the degree of interference in life caused by IBS symptoms assessed by patients.Compared with patients in the placebo group, patients in the active treatment groups (standard and individualized CHM) had significant improvement in bowel symptom scores as rated by patients (P=.03) and by gastroenterologists (P=.001), and significant

1998 JAMA

172. Abnormal colonic fermentation in irritable bowel syndrome. (PubMed)

Abnormal colonic fermentation in irritable bowel syndrome. The cause of irritable bowel syndrome (IBS) is unknown. It may follow gastroenteritis and be associated with an abnormal gut flora and with food intolerance. Our study was designed to assess whether these factors were associated with colonic malfermentation.We carried out a crossover controlled trial of a standard diet and an exclusion diet matched for macronutrients in six female IBS patients and six female controls. During the final

1998 Lancet

173. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

1998 DARE.

174. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials

Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Talley N J, Owen B K, Boyce P, Paterson K Authors' objectives To determine whether psychological treatments are of value in irritable bowel syndrome (IBS). Searching The studies were identified by searching (...) issues in the future should lead to a better understanding of the place of psychological treatments in IBS. The authors provide a list of recommendations (Table 6), based on their results, to assist those who may wish to design future trials in this field. Bibliographic details Talley N J, Owen B K, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. American Journal of Gastroenterology 1996; 91(2): 277-286 PubMedID Indexing Status

1996 DARE.

175. Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. (PubMed)

Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. 33 patients with refractory irritable bowel syndrome were treated with four 40-minute sessions of hypnotherapy over 7 weeks. 20 improved, 11 of whom lost almost all their symptoms. Short-term improvement was maintained for 3 months without further formal treatment. Hypnotherapy in groups of up to 8 patients was as effective as individual therapy.

1989 Lancet

176. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. (PubMed)

Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. 30 patients with severe refractory irritable-bowel syndrome were randomly allocated to treatment with either hypnotherapy or psychotherapy and placebo. The psychotherapy patients showed a small but significant improvement in abdominal pain, abdominal distension, and general well-being but not in bowel habit. The hypnotherapy patients showed a dramatic improvement in all features, the difference

1984 Lancet

177. Controlled study of psychotherapy in irritable bowel syndrome. (PubMed)

Controlled study of psychotherapy in irritable bowel syndrome. 101 outpatients with irritable bowel syndrome were randomly allocated to two treatment groups. Both groups received the same medical treatment, but patients in one group also received dynamically oriented individual psychotherapy in ten hour-long sessions spread over 3 months. After 3 months there was a significantly greater improvement in somatic symptoms in the psychotherapy group. The difference became more pronounced a year

1983 Lancet

178. Food hypersensitivity in irritable bowel syndrome. (PubMed)

Food hypersensitivity in irritable bowel syndrome. Food hypersensitivity as a cause of abdominal symptoms was investigated by means of exclusion diets and double-blind food provocation in patients with irritable bowel syndrome. Twenty-seven patients entered the study; nineteen complied with dietary manipulation. Food hypersensitivity as a cause of their presenting symptoms was confirmed by double-blind food provocation in only three patients, who also had evidence of associated atopic disease

1983 Lancet

179. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. (PubMed)

Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Specific foods were found to provoke symptoms of irritable bowel syndrome (IBS) in 14 of 21 patients. In 6 patients who were challenged double blind the food intolerance was confirmed. No difference was detected in changes in plasma glucose, histamine, immune complexes, haematocrit, eosinophil count, or breath hydrogen excretion produced after challenge or control foods. Rectal prostaglandin E2 (PGE2), however

1982 Lancet

180. Wheat fibre and irritable bowel syndrome. A controlled trial. (PubMed)

Wheat fibre and irritable bowel syndrome. A controlled trial. Twenty-six patients with irritable bowel syndrome entered a controlled trial of diets with a high or low wheat-fibre content. After 6 weeks on the high-wheat fibre regimen there was significant improvement in symptoms and an objective change in colonic motor activity. No such improvement occurred on the low-fibre regimen. Patients with irritable bowel syndrome should be encouraged to increase their daily intake of wheat fibre.

1977 Lancet